• 4831 Citations
20002020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My area of research is in genomics, immunotherapy and clinical trials for patients with thoracic malignancies.

Areas of Clinical Interest

Medical oncology, lung cancer

Fingerprint Dive into the research topics where Daniel Morgensztern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

van Brummelen, E. M. J., Levchenko, E., Dómine, M., Fennell, D. A., Kindler, H. L., Viteri, S., Gadgeel, S., López, P. G., Kostorov, V., Morgensztern, D., Orlov, S., Zauderer, M. G., Vansteenkiste, J. F., Baker-Neblett, K., Vasquez, J., Wang, X., Bellovin, D. I., Schellens, J. H. M., Yan, L., Mitrica, I. & 2 others, DeYoung, M. P. & Trigo, J., Apr 1 2020, In : Investigational New Drugs. 38, 2, p. 457-467 11 p.

Research output: Contribution to journalArticle

  • 2 Scopus citations
    Open Access
  • 2 Scopus citations

    Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

    Devarakonda, S., Govindan, R. & Morgensztern, D., Sep 14 2020, In : Cancer Cell. 38, 3, p. 320-322 3 p.

    Research output: Contribution to journalArticle

  • Nab-paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy

    Weiss, J. M., Pennell, N., Deal, A. M., Morgensztern, D., Bradford, D. S., Crane, J., West, H. J., Lee, C., Pecot, C., Stevenson, J. P., Irvin, W., Socinski, M., Stinchcombe, T., Villaruz, L. C. & Muss, H. B., Mar 1 2020, In : Cancer. 126, 5, p. 1060-1067 8 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

    Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., Li, M., Weaver, D. T., Vaikus, L., Keegan, M., Horobin, J. C. & Burns, T. F., Jan 2020, In : Lung Cancer. 139, p. 60-67 8 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations